Dapagliflozin found effective and safe in adults with advanced kidney disease

Results from DAPA-CKD trial indicate that SGLT2 inhibitors provide kidney- and cardiovascular-related benefits for this vulnerable patient population

2021-07-17

(Press-News.org) Highlights The sodium-glucose co-transporter 2 inhibitor dapagliflozin reduced kidney, cardiovascular, and mortality risks in patients with advanced chronic kidney disease, similar to benefits seen in individuals with normal or moderately impaired kidney function. Rates of serious side effects were similar in patients with advanced chronic kidney disease who received dapagliflozin or placebo.

Washington, DC (July 16, 2021) -- Studies have shown that diabetes drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors can provide kidney- and cardiovascular-related benefits to individuals with or without diabetes and with or without impaired kidney function. An analysis appearing in an upcoming issue of JASN now provides insights about the efficacy and safety of SGLT2 inhibitors in people with advanced chronic kidney disease (CKD), an especially vulnerable population.

For the analysis, Glenn M. Chertow, MD, MPH (Stanford University School of Medicine) and his colleagues examined data from the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, which enrolled patients with and without type 2 diabetes and with mildly decreased to severely decreased kidney function (stage 4 CKD).

In DAPA-CKD, 624 of 4,304 (14%) patients had stage 4 CKD--with an estimated glomerular filtration rate (eGFR), a measure of kidney function, as low as 25 mL/min/1.73m2--at the start of the study. Patients were randomized to receive daily treatments of the SGLT2 inhibitor dapagliflozin or placebo. Among patients with stage 4 CKD, those randomized to dapagliflozin experienced a 27% reduction in the primary endpoint (a composite of a sustained and large decline in kidney function, kidney failure, or death) and 29%, 17%, and 32% reductions in the kidney, cardiovascular, and mortality endpoints, respectively, compared with those randomized to placebo. Rates of serious side effects were similar in the two groups.

"This analysis shows that the effects of dapagliflozin in patients with stage 4 CKD are similar to effects in patients with mild to moderate CKD," said Dr. Chertow. "While patients with screening eGFR as low as 25 mL/min/1.73m2 were enrolled, it is noteworthy that neither dapagliflozin nor placebo were discontinued when eGFR declined, even to below 15 mL/min/1.73m2. Therefore, a drug initially developed for the treatment of diabetes can benefit patients with CKD with and without diabetes, including patients with moderate to advanced CKD."

INFORMATION:

Study co-authors include Priya Vart, Niels Jongs, Robert D. Toto, Jose Luis Gorriz, Fan Fan Hou, John J. V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Anna Maria Langkilde, David C. Wheeler, and Hiddo J. L. Heerspink.

Disclosures: G.M.C. has received fees from AstraZeneca for the DAPA-CKD trial steering committee, research grants from NIDDK, and Amgen; he is on the board of directors for Satellite Healthcare, has received fees for advisory boards for Ardelyx, Baxter, CloudCath, Cricket, DiaMedica, Durect, DxNow, Outset, and Reata; and holds stock options for Ardelyx, CloudCath, Durect, DxNow, and Outset; has received fees from Akebia, Gilead, Sanifit and Vertex for trial steering committees; and has received fees for DSMB service from Angion, Bayer and ReCor. P.V. and N.J. have no conflicts of interest to declare. R.D.T. has received support from AstraZeneca as a member of the executive committee for DAPA-CKD; is a consultant for Boehringer-Ingelheim; has participated on advisory boards for Bayer, and Relypsa; served on data monitoring committees for Akebia and Reata Pharmaceuticals; executive committee for Amgen; and as a faculty associate for Quest Diagnostics. J.L.G. has received honoraria for lectures AstraZeneca, Mundipharma, Eli Lilly and Novo Nordisk; and for advisory boards from AstraZeneca, Boehringer Ingelheim, Mundipharma and MSD. F.F.H. has received honoraria from AstraZeneca as a member of the executive member of the DAPA-CKD study; received honoraria from AbbVie for participation in a steering committee. J.J.V.M. has received support to his institution, Glasgow University, for work on clinical trials, consulting and other activities: Abbvie, Alnylam, Amgen, AstraZeneca, Bayer, BMS, Cardurion, Cyclerion, Cytokinetics, DalCor, GSK, Kidney Research UK, Merck, Novartis, Pfizer, Servier, Theracos. Vifor- Fresenius. He has received personal lecture fees: Abbott, Hickman, Sun Pharmaceuticals and Servier. R.C-R. has received fees from AstraZeneca for the DAPA-CKD trial steering committee; speaker fees from Boehringer Ingelheim, Amgen, and Janssen; research support from GlaxoSmithKline and Novo Nordisk; honoraria for advisory boards from Boehringer Ingelheim, Novo Nordisk and Medtronic. P.R. has received fees to his institution for research support from AstraZeneca and Novo Nordisk; for steering group participation from AstraZeneca, Gilead, Novo Nordisk, and Bayer; for lectures from Bayer, Eli Lilly and Novo Nordisk; and for advisory boards from Sanofi and Boehringer Ingelheim. C.D.S., B.V.S. and A.M.L. are employees and stockholders of AstraZeneca. D.C.W. provides ongoing consultancy services to AstraZeneca and has received honoraria and/or consultancy fees from Amgen, Astellas, Boehringer Ingelheim, Bayer, GlaxoSmithKline, Janssen, Napp, Mundipharma, Merck Sharp and Dohme, Reata, Tricida, and Vifor Fresenius. H.J.L.H. has received support from AstraZeneca to his institution for the DAPA-CKD trial; fees to his institution for his participation in advisory boards for Merck, Mitsubishi Tanabe, Janssen, and Mundipharma; as a consultant for AbbVie, Retrophin, Boehringer Ingelheim, and Novo Nordisk; for participation in steering committees for Janssen, Gilead, Bayer, Chinook, and CSL Pharma; and research support from AbbVie, AstraZeneca, Boehringer Ingelheim and Janssen.

The article, titled "Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease," will appear online at http://jasn.asnjournals.org/ on July 16, 2021, doi: 10.1681/ASN.2021020167.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the authors. ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit http://www.asn-online.org.

ELSE PRESS RELEASES FROM THIS DATE:

3D "assembloid" shows how SARS-CoV-2 infects brain cells

2021-07-16

Researchers at University of California San Diego School of Medicine and Rady Children's Institute for Genomic Medicine have produced a stem cell model that demonstrates a potential route of entry of SARS-CoV-2, the virus that causes COVID-19, into the human brain. The findings are published in the July 9, 2021 online issue of Nature Medicine. "Clinical and epidemiological observations suggest that the brain can become involved in SARS-CoV-2 infection," said senior author Joseph Gleeson, MD, Rady Professor of Neuroscience at UC San Diego School of Medicine and ...

Researchers surprised to find bacterial parasites behind rise of 'super bugs'

2021-07-16

PITTSBURGH, July 16, 2021 - For the first time ever, researchers from the University of Pittsburgh School of Medicine discovered that phages--tiny viruses that attack bacteria--are key to initiating rapid bacterial evolution leading to the emergence of treatment-resistant "superbugs." The findings were published today in Science Advances. The researchers showed that, contrary to a dominant theory in the field of evolutionary microbiology, the process of adaptation and diversification in bacterial colonies doesn't start from a homogenous clonal population. They were shocked to discover that the cause of much of the early adaptation wasn't random ...

Immune system May Need 'Continuing Education' to Protect Pregnancy

2021-07-16

Researchers at UC San Francisco are zeroing in on how the immune system may play a role in miscarriage, which affects about a quarter of pregnancies. Working in mice, the researchers have found that a recently discovered subset of cells in the immune system may prevent the mother's immune system from attacking the placenta and fetus. If the research is confirmed in further animal studies, and the cells play a similar role in people, they could point the way toward new therapies for pregnancies that are threatened by defects in immune tolerance. The researchers showed that pregnant mice who did not have this subset of cells, known as extrathymic Aire-expressing cells, were twice as likely to miscarry, and in many ...

From genes to memes: Algorithm may help scientists demystify complex networks

2021-07-16

UNIVERSITY PARK, Pa. -- From biochemical reactions that produce cancers, to the latest memes virally spreading across social media, simple actions can generate complex behaviors. For researchers trying to understand these emergent behaviors, however, the complexity can tax current computational methods. Now, a team of researchers has developed a new algorithm that can serve as a more effective way to analyze models of biological systems, which in turn allows a new path to understanding the decision-making circuits that make up these systems. The researchers add that the algorithm will help scientists study how relatively ...

Invention: The Storywrangler

2021-07-16

For thousands of years, people looked into the night sky with their naked eyes -- and told stories about the few visible stars. Then we invented telescopes. In 1840, the philosopher Thomas Carlyle claimed that "the history of the world is but the biography of great men." Then we started posting on Twitter. Now scientists have invented an instrument to peer deeply into the billions and billions of posts made on Twitter since 2008 -- and have begun to uncover the vast galaxy of stories that they contain. "We call it the Storywrangler," says Thayer Alshaabi, a doctoral student at the University of Vermont who co-led the new research. "It's like a telescope to look -- in real time -- at all this data that people ...

Add fatty acid to taste

2021-07-16

A new method developed by Institute for Systems Biology (ISB) and University of California, Riverside provides new insights into cancer biology by allowing researchers to show how fatty acids are absorbed by single cells. Fatty acids, along with glucose and amino acids, are a major energy source for cellular growth and proliferation, and abnormal fatty acid metabolism is often seen in cancer. Dr. Wei Wei's lab at ISB and Dr. Min Xue's lab at UC Riverside have been collaborating for years to develop a series of chemical probes and analytical approaches for quantifying cellular glucose uptake, lactate production, amino acid ...

Climate change to bring more intense storms across Europe

2021-07-16

Climate change is driving a large increase in intense, slow-moving storms, a new study by Newcastle University and the Met Office has found. Investigating how climate affects intense rainstorms across Europe, climate experts have shown there will be a significant future increase in the occurrence of slow-moving intense rainstorms. The scientists estimate that these slow-moving storms may be 14 times more frequent across land by the end of the century. It is these slow-moving storms that have the potential for very high precipitation accumulations, ...

Study finds vaccine hesitancy lower in poorer countries

2021-07-16

New research published in Nature Medicine reveals willingness to get a COVID-19 vaccine was considerably higher in developing countries (80% of respondents) than in the United States (65%) and Russia (30%). The study provides one of the first insights into vaccine acceptance and hesitancy in a broad selection of low- and-middle income countries (LMIC), covering over 20,000 survey respondents and bringing together researchers from over 30 institutions including the International Growth Centre (IGC), Innovations for Poverty Action (IPA), WZB Berlin Social Science Center, the Yale Institute for Global Health, the Yale Research Initiative on Innovation and Scale (Y-RISE), ...

Air-powered computer memory helps soft robot control movements

2021-07-16

Engineers at UC Riverside have unveiled an air-powered computer memory that can be used to control soft robots. The innovation overcomes one of the biggest obstacles to advancing soft robotics: the fundamental mismatch between pneumatics and electronics. The work is published in the open-access journal, PLOS One. Pneumatic soft robots use pressurized air to move soft, rubbery limbs and grippers and are superior to traditional rigid robots for performing delicate tasks. They are also safer for humans to be around. Baymax, the healthcare companion robot in the 2014 animated Disney film, Big Hero 6, is a pneumatic robot for good reason. But existing systems for controlling pneumatic soft robots still use electronic valves ...

Enabling the 'imagination' of artificial intelligence

2021-07-16

Imagine an orange cat. Now, imagine the same cat, but with coal-black fur. Now, imagine the cat strutting along the Great Wall of China. Doing this, a quick series of neuron activations in your brain will come up with variations of the picture presented, based on your previous knowledge of the world. In other words, as humans, it's easy to envision an object with different attributes. But, despite advances in deep neural networks that match or surpass human performance in certain tasks, computers still struggle with the very human skill of "imagination." Now, a USC ...

Dapagliflozin found effective and safe in adults with advanced kidney disease

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: